Field Medical Secures $40 Million to Transform Cardiac Ablation Technology for Ventricular Tachycardia

Field Medical Secures $40 Million in Funding

Field Medical Inc., a leading innovator in cardiac pulsed field ablation (PFA) technology, announced the successful completion of a $40 million Series A funding round on April 22, 2025. This funding, which includes $20 million in new capital along with the conversion of $20 million in debt from the seed round, highlights the strong confidence investors have in the company's initial focus on ventricular tachycardia (VT) and the versatile applications of its technology.

Purpose and Impact of the Funding

The secured funds will allow Field Medical to execute two pivotal pilot studies: VCAS for VT and Field PULSE for atrial fibrillation (AF). The financing will also support the ongoing development of the company's commercial PFA system and its operational expansion in preparation for VERITAS, a significant trial focusing on VT.

Dr. Steven Mickelsen, the CEO and founder of Field Medical, expressed the large implications of this funding: “This is a crucial milestone on our path to redefine how electrophysiologists approach ablation therapy. With our investors' support, we are accelerating the development of the FieldForce™ ablation system and making substantial strides towards our goal of broadening access to next-generation PFA solutions in cardiac ablation.”

The Technology Behind Field Medical

The company’s innovative solutions target a wide range of cardiac arrhythmias, including both VT and AF. The FieldForce Ablation System, notable for being the first to feature a purpose-built focal PFA catheter equipped with contact force technology, facilitates immediate ablation workflows, ensuring therapy can be conducted in a fraction of a second. Recent pilot study results, including VCAS for VT and PULSE for AF, demonstrate the system's versatility and efficacy.

At the heart of its operations is FieldBending™, a proprietary technology developed to deliver short, high-intensity electrical fields. This positions their system as a unique and advanced solution for treating the full spectrum of cardiac rhythm disturbances.

Company Background and Future Prospects

Founded in 2022, Field Medical has its sights set on developing next-generation PFA technologies that address the complex demands of modern cardiac ablation. Led by Dr. Steven Mickelsen, a pioneer in pulsed electric field technology, the company leverages his foundational work in PFA to propel innovative advancements in this healthcare space. Impressively, in 2024, Field Medical received the Breakthrough Device Designation from the FDA and was accepted into the TAP Pilot Program, underscoring the potential of their technology.

Market Insights

Ventricular tachycardia and atrial fibrillation represent two of the most common and serious arrhythmias, contributing to severe health issues such as strokes, heart failure, sudden cardiac death, and escalating healthcare costs. In the United States and Europe alone, VT and premature ventricular contractions (PVCs) affect over 6 million individuals, while AF is suspected to impact 2% to 6% of the global population.

The catheter ablation market for atrial fibrillation is projected to grow from approximately $5 billion to over $11 billion by 2034, with an annual growth rate between 13% and 16%. In comparison, the worldwide market for VT, which encompasses both devices and catheter ablations, was valued at around $12.5 billion in 2021, expected to reach $17 billion by 2027 with a steady annual growth rate of approximately 5.26%.

This evolving landscape indicates a significant increase in the acceptance and demand for catheter-based interventions to treat VT, driven by both technological advancements and clinical evidence capturing greater efficacy.

Field Medical's focus and commitment to innovation areas signal a promising trajectory in an industry ready for transformation, particularly as it moves toward granting unprecedented access to advanced cardiac care solutions.

For further information about Field Medical, visit their official site at www.fieldmedicalinc.com and connect with them on LinkedIn and X.

Note: The FieldForce™ Ablation System is a research device and is only permitted to be used for research purposes according to federal law.